María Río, Vice President and Managing Director of Gilead Spain, together with Cristóbal Belda of the Carlos III Institute of Health, signed the cooperation agreement for this week’s meeting. The IX Gilead Fellowships for Biomedical Research is highlighted by the healthcare sector in Spain this year, featuring a donation of 950 thousand euros to support innovative research efforts.
The edition’s core advancement expands beyond HIV, viral hepatitis C and Delta, and includes investments in hemato-oncology, COVID-19, invasive fungal infections, and top research articles in Medical Oncology. The program will depend on the collaboration of leading scientific communities and collaborative groups across the therapeutic areas involved in this call.
In her remarks, María Río, Vice President and Managing Director of Gilead Spain, expressed pride in the company’s ongoing contribution to Spanish research. She noted that the Biomedical Research Fellowships represent a cherished initiative and welcomed the Ninth Edition. The decision to include Oncology among the funded areas is expected to provide substantial support for researchers seeking to generate meaningful knowledge in this specialty, as has been achieved in other domains in prior editions. [Citation: Gilead Spain leadership]
Cristóbal Belda, director of the Carlos III Institute of Health, stated that ISCIII will continue to back and encourage these dual-focused initiatives that advance biomedical and health research. The collaboration with the fellowships serves as a tangible example of the Institute’s commitment to science and knowledge creation for the benefit of citizens and patients. [Citation: ISCIII leadership]
At the service of biomedical research
The Gilead Biomedical Research Fellowships were established in 2013 to promote biomedical research within clinical care centers. With a total investment of 7.5 million euros, Spain has become a benchmark in the health sector. In that period, 535 research projects were submitted, of which 145 were selected, spanning 13 autonomous communities and 47 care centers. ISCIII’s collaboration ensures the project review process aligns with the principles of transparency, objectivity, and independence necessary for fair funding decisions. [Citation: Gilead ISCIII collaboration]
Applicants must prepare proposals in English and submit them online by July 12. Each principal investigator may present only one research project, and a maximum of two proposals may be allowed per treatment area and health center to which the investigator is affiliated. An independent evaluation committee of international reviewers, appointed by the Carlos III Institute of Health, will be responsible for reviewing and prioritizing the proposals. [Citation: Application guidelines]